Tuberculosis and anti-TNF treatment: Experience of a central London hospital

Clinical Rheumatology

Volumn 30, Issue 3, 2011, Pages 399-401

  Mankia, Satveer ^a   Peters, James E ^a   Kang, Swan ^a   Moore, Samantha ^a   Ehrenstein, Michael R ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anti TNF; Screening; TB

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL PRACTICE; HEALTH CARE PERSONNEL; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SCREENING; THORAX RADIOGRAPHY; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOGLOBULIN G; LATENT TUBERCULOSIS; LONDON; RECEPTORS, TUMOR NECROSIS FACTOR; TUBERCULOSIS;

EID: 79954627402     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1605-1     Document Type: Article

References (10)

1. YP Goekoop-Ruiterman JK de Vries-Bowstra CF Allaart, et al. 2008 Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomised controlled trial Arthritis Rheum 58 S126 S135 18240203 10.1002/art.23364 1:STN:280: DC%2BD1c3ivFykuw%3D%3D
2. LP Omerod HJ Milburn S Gillespie J Ledingham D Rampton 2005 BTS recommendations for assessing risk, and for managing M. tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment Thorax 60 800 805 10.1136/thx.2005.046797 (Pubitemid 41475202)
3. Anderson C, Moore J, Kruijshaar M, Abubakar I. (2008) Tuberculosis in the UK. Annual Report on Tuberculosis Surveillance in the UK 2008. London: Health Protection Agency Centre for Infections.
4. Global tuberculosis control: epidemiology, financing, strategy: WHO report 2009.
5. WG Dixon KL Hyrich KD Watson M Lunt J Galloway A Ustianowski 2010 Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) Ann Rheum Dis 69 522 528 19854715 10.1136/ard.2009.118935 1:CAS:528:DC%2BC3cXksVKgs7c%3D
6. GR Burmester X Mariette C Montecucco, et al. 2007 Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the research in active rheumatoid arthritis (ReAct) trial Ann Rheum Dis 66 732 739 17329305 10.1136/ard.2006. 066761 1:CAS:528:DC%2BD2sXntlOnu7Y%3D (Pubitemid 46846691)
7. F Tubach D Salmon P Ravaud, et al. 2009 Risk of tuberculosis is higher with anti-tumour necrosis factor monoclonal antibody therapy than with soluble tumour necrosis factor therapy: the three-year prospective French research axed on tolerance of biotherapies registry Arthritis Rheum 60 1884 1894 19565495 10.1002/art.24632 1:CAS:528:DC%2BD1MXptlKktLo%3D
8. KG Saag GG Teng NM Patkar, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762 784 18512708 10.1002/art.23721 1:CAS:528:DC%2BD1cXot1Wgs74%3D (Pubitemid 351847559)
9. O Infuso D Falzon 2006 European survey of BCG vaccination policies and surveillance in children, 2005 Euro Surveill 11 6 11 16567882 1:STN:280:DC%2BD28rltlyntg%3D%3D
10. I Sauzullo F Mengoni R Scrivo, et al. 2010 Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patients candidate for anti-tumour necrosis-alpha treatment Int J Tuberc Lung Dis 14 834 840 20550765 1:STN:280:DC%2BC3crgslWgsA%3D%3D